Drugmaker Valeant to feel sting of closing controversial pharmacy

UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS

(Updated - November 11, 2015 9:49 AM EST)

(correction: price target is $255)

UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More

Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura

Nomura Securities analyst Shibani Malhotra lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $175.00 (from $220.00) but reiterated a Buy rating as her "Conservative Base Case" suggest 109% upside to current levels.

While the call did not address all our outstanding questions; however,... More

BMO 'Incrementally Positive' on Valeant (VRX) Following Conf. Call; Still See N-T Headline Risk Affecting Shares

BMO Capital is out with commentary on Valeant Pharma (NYSE: VRX) following today's conference call.

Analyst Alex Arfaei said the firm is incrementally positive on Valeant following the event. The analyst believes management provided good commentary about their near-term plans, and status of business operations. The focus now is on the remaining headline risk and execution in 2016.

Arfai sees near-term headline risk on Valeant as medium-to-high until the conclusion of the committee's investigation, at the earliest. The analyst commented, Valeants business is under high... More

Valeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'

With its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.

CEO Michael Pearson also the company "is going to survive" and... More